Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot

Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases, involving bivalent antibody-mimetic scaffolds and novel peptides.  

Scaffolding
New protein scaffolds are being used to develop antibody-mimetics • Source: Shutterstock

Alexion Pharmaceuticals Inc. is continuing to search out potential novel therapies in the complement and rare diseases spaces, areas it knows well, with the latest candidates expected to come from collaborations with two Scandinavian biotechs, Sweden’s Affibody AB and Denmark’s Zealand Pharma AS, in deals worth a potential combined value of $1.3bn.

Boston, MA-based Alexion has entered into other tie-ups in the rare diseases area over the past year or so, involving...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.